CCCC
Price
$3.18
Change
+$0.01 (+0.32%)
Updated
Oct 22 closing price
Capitalization
391.22M
13 days until earnings call
Intraday BUY SELL Signals
EPRX
Price
$7.59
Change
-$0.14 (-1.81%)
Updated
Oct 22 closing price
Capitalization
501.5M
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CCCC vs EPRX

CCCC vs EPRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CCCC vs. EPRX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CCCC is a Buy and EPRX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CCCC with price predictions
Oct 22, 2026

CCCC's RSI Indicator recovers from oversold territory

The RSI Oscillator for CCCC moved out of oversold territory on October 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 34 of the 41 cases the stock moved higher. This puts the odds of a move higher at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CCCC as a result. In 68 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for CCCC just turned positive on October 19, 2026. Looking at past instances where CCCC's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.

Following a +0.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCCC advanced for three days, in 196 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

CCCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CCCC entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.582) is normal, around the industry mean (2.973). P/E Ratio (-3.495) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (10.989) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. CCCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for EPRX with price predictions
Oct 22, 2026

EPRX in +11.22% Uptrend, rising for three consecutive days on October 21, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EPRX advanced for three days, in 100 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on EPRX as a result. In 57 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

The Moving Average Convergence Divergence (MACD) for EPRX just turned positive on October 22, 2026. Looking at past instances where EPRX's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.

EPRX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for EPRX moved above the 200-day moving average on October 05, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

EPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 92 of 132 cases where EPRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Bearish Trend Analysis

The 10-day RSI Indicator for EPRX moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for EPRX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.642) is normal, around the industry mean (2.973). P/E Ratio (-7.441) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 39 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. EPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
CCCC: Fundamental Ratings
CCCC
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
53
P/E GROWTH RATING
1..100
28
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CCCCEPRX
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
68%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
53%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
63%
Advances
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 9 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
70%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CCCC: $3.18 vs. EPRX: $7.59)
Brand notoriety: CCCC and EPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CCCC: 71% vs. EPRX: 36%
Market capitalization -- CCCC: $391.22M vs. EPRX: $501.5M
CCCC [@Biotechnology] is valued at $391.22M. EPRX’s [@Biotechnology] market capitalization is $501.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CCCC’s FA Score shows that 2 FA rating(s) are green while EPRX’s FA Score has 1 green FA rating(s).

  • CCCC’s FA Score: 2 green, 3 red.
  • EPRX’s FA Score: 1 green, 4 red.
According to our system of comparison, EPRX is a better buy in the long-term than CCCC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CCCC’s TA Score shows that 5 TA indicator(s) are bullish while EPRX’s TA Score has 7 bullish TA indicator(s).

  • CCCC’s TA Score: 5 bullish, 3 bearish.
  • EPRX’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, EPRX is a better buy in the short-term than CCCC.

Price Growth

CCCC (@Biotechnology) experienced а +14.39% price change this week, while EPRX (@Biotechnology) price change was +12.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

CCCC is expected to report earnings on Nov 05, 2026.

EPRX is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CCCC
Daily Signal:
Gain/Loss:
EPRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

EPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, EPRX has been loosely correlated with IMNM. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if EPRX jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EPRX
1D Price
Change %
EPRX100%
-1.81%
IMNM - EPRX
35%
Loosely correlated
+1.44%
ASMB - EPRX
35%
Loosely correlated
-0.88%
LKFT - EPRX
33%
Loosely correlated
+2.68%
EDIT - EPRX
33%
Loosely correlated
-0.80%
TARS - EPRX
33%
Loosely correlated
+2.24%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASMB20.28-0.18
-0.88%
Assembly Biosciences
AUR4.86-0.15
-2.99%
Aurora Innovation
DTI1.70-0.12
-6.59%
Drilling Tools International Corp
BJDX0.63-0.05
-6.94%
Bluejay Diagnostics Inc.
EZPW29.35-3.85
-11.60%
EZCORP